Navigation Links
A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
Date:9/19/2012

STOCKHOLM, September 20, 2012 /PRNewswire/ --

Medivir AB (OMX: MVIR), announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly developed by Medivir and Janssen Research & Development Ireland (Janssen). TMC647055 is a potent NNI (non-nucleoside inhibitor) of the HCV NS5B polymerase and is being developed by Janssen R&D.

"This study is in line with Medivir's and Janssen's strategy to evaluate different combination possibilities with simeprevir for interferon-free HCV treatments. This will broaden our understanding of simeprevir, which we believe has the necessary characteristics to potentially become a key component of future hepatitis C treatment regimens, including combination with interferon and ribavirin as well as interferon-free therapies," comments Charlotte Edenius, Medivir's EVP of Research and Development.

Study design

This will be an open label study in patients who are chronically infected with HCV genotype-1a or 1b to assess the efficacy, safety and tolerability of the combination. The primary endpoint in the study will be SVR12 (sustained virologic response 12 weeks after end of treatment). Simeprevir, TMC647055 and low-dose ritonavir will be co-administered once daily, with and without ribavirin.

Approximately 40 patients will be enrolled in this study, which is divided in two parts. The first part will include patients chronically infected with HCV genotype-1, who are either treatment-naive or have relapsed after prior pegylated interferon (PegIFN)/ribavirin treatment. The treatment will consist of simeprevir, TMC647055 and low-dose ritonavir, with and without ribavirin for 12 weeks.

The second part of the trial will investigate the same regimen in prior null r
'/>"/>

SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
4. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
5. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
6. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
7. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
9. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
10. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... November 26, 2014 SoundConnect , ... is proud to announce that Darren Suders has joined ... Darren will drive the partner program ... experience. , Darren brings more than 10-years ... key roles in channel operations, from policy development, to ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... , , WATERTOWN, Mass., Sept. 10 ... breakthrough synthetic chemistry technology announced today that it will ... on the synthesis and antibacterial activity of analogs from ... at the 49th Interscience Conference on Antimicrobial Agents and ...
... STOCKHOLM, September 10 Pergamum AB has announced ... wound healing interests, and create a broad-based therapeutic ... The Pergamum product pipeline consists of five ... Indications covered within the,portfolio include improved wound healing ...
... , , , ... Inc. (PTC) today announced the initiation of a Phase 3 ... in patients with nonsense mutation cystic fibrosis (nmCF). Patients ... conductance regulator (CFTR) protein, a chloride channel necessary for normal ...
Cached Biology Technology:Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... predator. Except when that predator runs so fast that it ... size, is the fastest creature on Earth. Some of these ... about five miles per hour). The fastest human can do ... the tiger beetle, a person would have to hit 480 ... problem. At peak speeds, everything becomes a blur. They can,t ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... novel method of collecting and storing carbon dioxide that will ... The quest to capture carbon dioxide is crucial to ... compressed and safely stored. It is also a ... and require several stages of refining and extraction before a ...
... antibiotic and anti-cancer chemicals may one day be synthesised ... that combine to provide soldier beetles with their potent ... Sweden,s Karolinska Institute, published details of the gene identification ... Nature Communications ., "For the first time, our ...
... skin and well-armored bodies. So it comes as something of a ... the most acute in the animal kingdom. The crocodilian sense ... that dot their skin all over their body. In alligators, the ... study, published in the Nov. 8 issue of the Journal ...
Cached Biology News:Capturing carbon with clever trapdoors 2Gene find turns soldier beetle defence into biotech opportunity 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 3
... system for fluorescent light due to small ... camera to detect low level light in ... disease research, gene expression, circadian rhythm, gels ... imager with a motor-driven camera inside the ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: